Dr. Chatterjee is a med-peds trained primary care and addiction medicine physician at several shelter-based clinics through Boston Health Care for the Homeless Program. His areas of clinical and research interest include innovative treatment models for opioid use disorder in marginalized populations, and interventions on social determinants of health, such as food insecurity. He has an additional interest in racism and health care, particularly its manifestations in medical education and training.
Diversity, Equity, Inclusion and Accessibility
My Diversity/Equity Inclusion work has taken several forms:
I have worked to explore the role of racism in health professions admissions and in medical education. I and my colleagues have written several papers on bias due to race, gender, and other factors during the interview process to medical school and other health profession programs. While at Harvard Medical School, I was the faculty advisor for the Racial Justice Coalition and in that role, worked to expand and improve the curriculum with regard to its discussion of racism in health care. As part of that role, I have mentored several students in writing papers describing these efforts.
Secondly, I have worked to explore the role of racism in the conceptualization and treatment of addiction in the United States. In my role on the Healing Communities Study, I helped found the Racial Equity and Social Justice committee, which works to improve efforts to incorporate intentional efforts to promote equity in addiction treatment. We describe our work in a paper in the American Journal of Public Health, but the racial equity work we are undertaking is ongoing.
I serve in several committee roles at BMC and in national organizations. I serve on the Boston University Medical Group (BUMG) Diversity and Inclusion Advisory Council, as well as the Section of General Internal Medicine's Anti-Racism committee. I also serve on AMERSA's Diversity Committee. In that role, I am leading a subcommittee that is developing a bibliography of papers on other resources examining the role of racism in addiction treatment.
Evans Center for Interdisciplinary Biomedical Research
Boston University Chobanian & Avedisian School of Medicine
Clinical Addiction Research and Education Unit
Rapid measurement of novel harm reduction housing on HIV risk, treatment uptake, drug use and supply
05/01/2023 - 04/30/2025 (PI)
Brandeis University National Institute o
Together We Rize 5th Anniversary Grant Program: Shelter Harm Reduction
12/02/2022 - 12/01/2023 (PI)
Evaluation of the Community Care in Reach(R) Mobile Addiction Initiative for Youth and Young Adults (YYA)
12/01/2021 - 11/30/2023 (PI)
Massachusetts General Hospital
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
to make corrections and additions.
Showing 10 of 47 results.
Zang X, Walley AY, Chatterjee A, Kimmel SD, Morgan JR, Murphy SM, Linas BP, Nolen S, Reilly B, Urquhart C, Schackman BR, Marshall BDL. Changes to opioid overdose deaths and community naloxone access among Black, Hispanic and White people from 2016 to 2021 with the onset of the COVID-19 pandemic: An interrupted time-series analysis in Massachusetts, USA. Addiction. 2023 Aug 28.View Related Profiles. PMID: 37640687; DOI: 10.1111/add.16324;
Chatterjee A, Yan S, Lambert A, Morgan JR, Green TC, Jeng PJ, Jalali A, Xuan Z, Krieger M, Marshall BDL, Walley AY, Murphy SM. Comparison of a national commercial pharmacy naloxone data source to state and city pharmacy naloxone data sources-Rhode Island, Massachusetts, and New York City, 2013-2019. Health Serv Res. 2023 Oct; 58(5):1141-1150.View Related Profiles. PMID: 37408299; PMCID: PMC10480090; DOI: 10.1111/1475-6773.14200;
Swartz N, Odayappan S, Chatterjee A, Cutler D. Impact of Medicaid expansion on inclusion of medications for opioid use disorder in homeless adults' treatment plans. J Subst Use Addict Treat. 2023 Sep; 152:209059. PMID: 37207834
Dang N, Khunte M, Zhong A, Chatterjee A. Naloxone Online Information Exceeds the Recommended Reading Level for Patient Education Materials. J Stud Alcohol Drugs. 2023 Apr 19. PMID: 37096779; DOI: 10.15288/jsad.22-00343;
Chatterjee A, Bannister M, Hill LG, Davis CS. Prescribing Syringes to People Who Inject Drugs: Advancing Harm Reduction in Primary Care. J Gen Intern Med. 2023 Jun; 38(8):1980-1983. PMID: 37020124; PMCID: PMC10271981; DOI: 10.1007/s11606-023-08183-7;
Chatterjee A, Weitz M, Savinkina A, Macmadu A, Madushani RWMA, Potee RA, Ryan D, Murphy SM, Walley AY, Linas BP. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts. JAMA Netw Open. 2023 Apr 03; 6(4):e237036.View Related Profiles. PMID: 37058306; PMCID: PMC10105308; DOI: 10.1001/jamanetworkopen.2023.7036;
Chatterjee A, Dunleavy S, Gonzalez T, Benson J, Henault L, MacIntosh A, Goodell K, Witzburg R, Paasche-Orlow M. Health professions school applicant experiences of discrimination during interviews. Med Teach. 2023 May; 45(5):532-541.View Related Profiles. PMID: 36369780
Nolen S, Zang X, Chatterjee A, Behrends CN, Green TC, Linas BP, Morgan JR, Murphy SM, Walley AY, Schackman BR, Marshall BDL. Evaluating equity in community-based naloxone access among racial/ethnic groups in Massachusetts. Drug Alcohol Depend. 2022 Dec 01; 241:109668.View Related Profiles. PMID: 36309001; PMCID: PMC9833886; DOI: 10.1016/j.drugalcdep.2022.109668;
Morgan JR, Freibott CE, Jalali A, Jeng PJ, Walley AY, Chatterjee A, Green TC, Nolan ML, Linas BP, Marshall BDL, Murphy SM. The role of increasing pharmacy and community distributed naloxone in the opioid overdose epidemic in Massachusetts, Rhode Island, and New York City. Drug Alcohol Depend Rep. 2022 Sep; 4.View Related Profiles. PMID: 36337350; PMCID: PMC9631422; DOI: 10.1016/j.dadr.2022.100083;
Adams JW, Savinkina A, Fox A, Behrends CN, Madushani RWMA, Wang J, Chatterjee A, Walley AY, Barocas JA, Linas BP. Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs. Addiction. 2022 Oct; 117(10):2635-2648.View Related Profiles. PMID: 35315148; PMCID: PMC9951221; DOI: 10.1111/add.15883;
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.